RGNX REGENXBIO Inc.

NASDAQ
$7.18

REGENXBIO Inc. (RGNX) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $1.26 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.3% since its last earnings release on November 5, 2026.

REGENXBIO Beat Consensus Estimates
Thursday, November 5, 2026 · 7:05 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 7:05 AM ET
Earnings Whisper
-
vs ($1.26)
Rev est $11.38M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.77

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.